Drug Trial Radar · NCT06107205
Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Nov 7, 2023
Primary completion
Dec 14, 2023
Study completion Dec 14, 2023
Sponsor
- Lead sponsor
- Shanghai Auzone Biological Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the randomization sequence.
Conditions
- Healthy Adult Subjects
Interventions
TTYP01Drug
1 single oral dose of 90 mg TTYP01 (3 tablets of the test drugs, test formulation T)
RadicavaDrug
1 injection of 60 mg Radicava (reference drug R1, intravenous infusion of 60 mg administered over 60 minutes)
Radicava ORSDrug
1 single oral dose of 105 mg/5 mL Radicava ORS (reference drug R2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK Parameters-Area under the plasma concentration-time curve (AUC0-inf) from time 0 extrapolated to infinity of unchanged edaravone after TTYP01, Radicava and Radicava ORS administrationTime frame: up to 48 hours each postdose
- PK Parameters- AUC from time 0 to the last measurable non-zero concentration(AUC0-t)of unchanged edaravone after TTYP01, Radicava and Radicava ORS administrationTime frame: up to 48 hours each postdose
- PK Parameters - Maximum observed concentration (Cmax) of unchanged edaravone after TTYP01, Radicava and Radicava ORS administrationTime frame: up to 48 hours each postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Early Phase Services
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.